Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 12/20 | 0.63 |
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | RXRA | P19793 | 6/20 | 0.56 |
| ▸ | RXRB | P28702 | 5/20 | 0.56 |
| ▸ | RXRG | P48443 | 5/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574038 | 0.93 | PPARD (0.67) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3570631 | 0.90 | PPARD (0.57) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3573491 | 0.89 | PPARD (0.62) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL478042 | 0.89 | PPARD (0.65) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3573400 | 0.88 | PPARD (0.63) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3574383 | 0.88 | PPARD (0.63) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3576259 | 0.85 | PPARD (0.57) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3579302 | 0.84 | PPARD (0.56) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3574075 | 0.84 | PPARD (0.56) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3569504 | 0.83 | PPARD (0.64) | PPARDPPARAPPARGRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825160-B2 | such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity | CELLZOME LIMITED (GB) | 2010-11-02 | — | — | US | claimed |
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | CELLZOME AG (DE) | 2009-05-07 | — | — | US | claimed |
| EP-1805129-B1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME LTD (GB) | 2009-03-18 | — | — | EP | claimed |
| US-7825160-B2 | such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity | CELLZOME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | CELLZOME AG (DE) | 2009-05-07 | — | — | US | disclosed |
| EP-1805129-B1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | BACE1, BACE2, APP | PPARD 455/4885PPARA 327/4885PPARG 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.